1. In Vivo

From Newton to Heisenberg--The New Physics of the Drug Industry

While the current wave of high profile drug industry deals recalls the heady days of 1980s consolidation, the motivations are quite different. Managed care is forcing companies to prize the efficient leveraging of assets, not critical mass. In today's drug industry, companies will manage for strategic diversity, juggling a number of different platforms at one time. Successful companies will by no means all have been successful using the same set of tools.

Only a year and a half ago, all the major drug companies had quickly set up planning teams to analyze the meaning for their companies of Merck & Co. Inc. ’s acquisition of Medco Containment Services Inc. Over the next year, the answers seemed to come in, as SmithKline Beecham PLC, Pfizer Inc. , and Eli Lilly & Co. all made their moves with PBMs. Only Roche Holdings Ltd.’s acquisition of Syntex Corp., an apparent throwback to old-style consolidation thinking, disturbed the smooth flow of the new industry logic.

Then the tone of the activity changed, and Roche-Syntex no longer seemed like an outlier. American Home Products Corp. attacked...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.